Law Firm Investigates ADMA Biologics for Securities Fraud After 29% Stock Plunge
ADMA sits 28% above its 52-week low of $7.21 on elevated volume (4.9× avg).
Summary
A securities law firm, Bleichmar Fonti & Auld LLP, has announced an investigation into ADMA Biologics for potential violations of federal securities laws. This investigation follows a 29% stock decline that occurred between March 23 and March 25, 2026, after Culper Research published a report on March 24, 2026, alleging channel stuffing and misrepresentation of 2025 revenue growth. While the short-seller report and the initial stock reaction were previously known and addressed by the company in recent news and an 8-K filing, the initiation of a formal legal investigation by a law firm introduces new legal and financial risks for ADMA Biologics. Investors should monitor developments regarding this investigation and any potential class-action lawsuit.
At the time of this announcement, ADMA was trading at $9.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $7.21 to $25.67. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Access Newswire.